The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 23, 2025

Filed:

Dec. 17, 2019
Applicants:

Max-delbrück-centrum Für Molekulare Medizin IN Der Helmholtz-gemeinschaft, Berlin, DE;

Charité—universitätsmedizin Berlin, Berlin, DE;

Inventors:

Thomas Blankenstein, Berlin, DE;

Antonio Pezzutto, Berlin, DE;

Simone Rhein, Berlin, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); A61K 38/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61P 35/00 (2018.01); C07K 14/70596 (2013.01); C07K 14/71 (2013.01); A61K 38/00 (2013.01);
Abstract

The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer, in particular, of B cell lymphoma or B cell leukemia. The invention provides a nucleic acid encoding TCR alpha or beta chain constructs of TCR constructs capable of specifically binding to a peptide of SEQ ID NO: 1, derived from the lineage specific antigen CD22, in the context of HLA-A2 and to subsequently lyse CD22-positive cells. The invention further provides a corresponding protein and host cell. e.g., a CD8+ T cell, pharmaceutical compositions comprising the same, and therapeutic use for treatment of B cell lymphoma or B cell leukemia, such as diffuse large B-cell lymphoma (DLBCL).


Find Patent Forward Citations

Loading…